Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Hepatobiliary System and PancreasDRG 437-malignancy-of-hepatobiliary-system-or-pancreas-without-cc-mcc
    Ask Trek AI about this page

    Malignancy of Hepatobiliary System or Pancreas without CC/MCC: Inpatient Reimbursement Overview

    DRG 437 encompasses inpatient stays for malignancy of the hepatobiliary system or pancreas without Complication or Comorbidity or Major Complication or Comorbidity, covering surgical and medical management of these cancers. It matters for inpatient reimbursement because DRG assignment drives Medicare payment weights and proper documentation and coding influence hospital revenue.

    Customize your policy alerts

    Sign up for drg 437 policy alerts

    Get alerted when payer policies referencing 437 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 437 Overview

    DRG 437 covers inpatient admissions for malignant disease of the hepatobiliary system or pancreas when there are no Major Complication or Comorbidity and no Complication or Comorbidity present. Typical cases include resections, biliary bypass, or palliative procedures for pancreatic or hepatobiliary malignancies without significant additional diagnoses. This Diagnosis-Related Group is important for Medicare payment because case assignment affects base payment weights and hospital reimbursement for these oncology-related surgical and medical inpatient stays. Accurate coding of the primary diagnosis and any comorbid conditions determines whether an admission remains in this DRG or is shifted to a higher-paying group.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Neoadjuvant and adjuvant therapy trials for resectable hepatobiliary and pancreatic malignancies: These studies evaluate chemotherapy, chemoradiation, or multimodal regimens given before (neoadjuvant) or after (adjuvant) surgical resection in patients with localized hepatocellular carcinoma, cholangiocarcinoma, or pancreatic ductal adenocarcinoma without major complications. The patient population typically includes clinically operable cases or high-risk resectable tumors, and the objective is to improve margin-negative resection rates, reduce recurrence, and increase disease-free survival; results inform surgical planning, perioperative resource use, and downstream costs relevant to inpatient reimbursement and length-of-stay considerations. - Comparative effectiveness and perioperative management trials: These trials compare surgical approaches (open versus minimally invasive), anesthesia and enhanced recovery after surgery (ERAS) protocols, or blood management strategies in patients undergoing hepato-pancreato-biliary procedures for malignancy without CC/MCC. The focus is on immediate perioperative outcomes—complication rates, transfusion needs, hospital stay, and readmission—and the population includes adults admitted for definitive surgical management; findings guide hospital protocols, resource allocation, and payer negotiations around expected costs and quality metrics for this DRG. - Real-world outcomes and survivorship studies for non-metastatic cases managed medically or with locoregional therapies: Observational cohort studies and registry analyses track longer-term outcomes, functional status, symptom burden, and healthcare utilization after inpatient episodes for patients receiving systemic therapy, ablation, or intra-arterial treatments who do not have major complications. These studies assess patterns of recurrence, post-discharge care needs, outpatient resource use, and transitions to palliative care in a population often requiring complex longitudinal management; insights are crucial for payers and providers to plan care pathways, bundle payments, and predict post-acute service use tied to this DRG.

    Related Codes

    405-PANCREAS-LIVER-AND-SHUNT-PROCEDURES-WITH-MCC

    Pancreas, Liver and Shunt Procedures with MCC: Inpatient Reimbursement Overview

    406-PANCREAS-LIVER-AND-SHUNT-PROCEDURES-WITH-CC

    Pancreas, Liver and Shunt Procedures with CC: Inpatient Reimbursement Overview

    407-PANCREAS-LIVER-AND-SHUNT-PROCEDURES-WITHOUT-CC-MCC

    Pancreas, Liver and Shunt Procedures without CC/MCC: Inpatient Reimbursement Overview

    408-BILIARY-TRACT-PROCEDURES-EXCEPT-ONLY-CHOLECYSTECTOMY-WITH-OR-WITHOUT-C-D-E-WITH-MCC

    Biliary Tract Procedures Except Only Cholecystectomy with or without C.D.E. with MCC: Inpatient Reimbursement Overview

    409-BILIARY-TRACT-PROCEDURES-EXCEPT-ONLY-CHOLECYSTECTOMY-WITH-OR-WITHOUT-C-D-E-WITH-CC

    Biliary Tract Procedures Except Only Cholecystectomy with or without C.D.E. with CC: Inpatient Reimbursement Overview

    410-BILIARY-TRACT-PROCEDURES-EXCEPT-ONLY-CHOLECYSTECTOMY-WITH-OR-WITHOUT-C-D-E-WITHOUT-CC-MCC

    Biliary Tract Procedures Except Only Cholecystectomy with or without C.D.E.: Inpatient Reimbursement Overview

    411-CHOLECYSTECTOMY-WITH-C-D-E-WITH-MCC

    Cholecystectomy with C.D.E. with MCC: Inpatient Reimbursement Overview

    412-CHOLECYSTECTOMY-WITH-C-D-E-WITH-CC

    Cholecystectomy with Common Duct Exploration with Complication or Comorbidity: Inpatient Reimbursement Overview

    413-CHOLECYSTECTOMY-WITH-C-D-E-WITHOUT-CC-MCC

    Cholecystectomy with C.D.E. without CC/MCC: Inpatient Reimbursement Overview

    414-CHOLECYSTECTOMY-EXCEPT-BY-LAPAROSCOPE-WITHOUT-C-D-E-WITH-MCC

    Cholecystectomy Except by Laparoscope without C.D.E. with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 35

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.